Table 1.
Selected clinical trials of genotype-based therapy
| Institute | Year | Sample size | Platform | Tissue sample | Patients with actionable mutations | Patients enrolled in genotype-matched trials | ORR of patients matched to treatment based on genotype |
|---|---|---|---|---|---|---|---|
| MD Anderson Cancer Center5 | 2015 | 2,000 | 11–50 gene panels | FFPE | 789/2,000 (39.5%) | 83/2,000 (4.2%) | Not available |
| Memorial Sloan Kettering Cancer Center2 | 2016 | 12,670 | 341 or 410 gene panels | FFPE | 3,792/10,336 (36.7%) | 527/5,009 (10.5%) | Not available |
| Dana-Farber/Harvard Cancer Center6 | 2016 | 3,727 | 275 gene panels | FFPE | 31/50 (62.0%) | 16/50 (32.0%) | Not available |
| Princess Margaret Cancer Centre4 | 2016 | 1,640 | 23–48 gene panels | FFPE | 25% | 84/1,640 (5.1%) | 19% |
| Gustave Roussy88 | 2017 | 1,035 | 30–75 gene panels + aCGH | FF | 411/1,035 (39.7%) | 199/1,035 (19.2%) | 11% |
| University of Michigan89 | 2017 | 556 | WGS, WES, RNAseq | FF | Not available | 3%–11% | Not available |
| Lyon90 | 2019 | 2,579 | 69 gene panels + aCGH | FFPE | 699/2,579 (27.1%) | 182/2,579 (7.1%) | 13% |
aCGH, array conparative genomic hybridization; WGS, whole-genome sequencing; WES, whole-exome sequencing; FFPE, formalin-fixed paraffin-embedded; FF, fresh-frozen; ORR, objective response rate.